Evidence map›Paper›PMID 37434208›Full record

ReviewMolecular neurodegeneration2023

Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer's disease.

Yasuteru Inoue, Francis Shue, Guojun Bu, Takahisa Kanekiyo

Open access · goldAbstract readReview
In one paragraph

Review in Molecular neurodegeneration, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 8 pooled it
52.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

182 citing papers in PubMed, 8 syntheses or guidelines pooled it, 255 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Special Issue "Molecular Insight into Alzheimer's Disease".International journal of molecular sciences · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. The bidirectional mechanistic links between Alzheimer's disease and cardiovascular disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  19. Article
  20. Article

122 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yasuteru InoueDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Francis ShueDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Guojun BuSciNeuro Pharmaceuticals, Rockville, MD, 20850, USA.
Takahisa KanekiyoDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. kanekiyo.takahisa@mayo.edu.ORCID 0000-0001-6751-9374
Mayo Clinic in Florida · USJacksonville College · US

Funding

Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Yingxue Ren · 2021 to 2026
$42.0M
Impact of ApoE2 on aging-related conditionsRF1AG057181 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2018 to 2018
$3.7M
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's DiseaseRF1AG068034 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2021 to 2022
$1.6M
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementiaRF1AG071226 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2021 to 2021
$1.2M
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementiaR01AG071226 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2024 to 2025
$775k
NIA NIH HHS R01 AG071226NIA NIH HHS RF1 AG057181NIA NIH HHS RF1 AG068034NIA NIH HHS RF1 AG071226NIA NIH HHS U19 AG069701
6 · The paper itself

Abstract

Vascular cognitive impairment and dementia (VCID) is commonly caused by vascular injuries in cerebral large and small vessels and is a key driver of age-related cognitive decline. Severe VCID includes post-stroke dementia, subcortical ischemic vascular dementia, multi-infarct dementia, and mixed dementia. While VCID is acknowledged as the second most common form of dementia after Alzheimer's disease (AD) accounting for 20% of dementia cases, VCID and AD frequently coexist. In VCID, cerebral small vessel disease (cSVD) often affects arterioles, capillaries, and venules, where arteriolosclerosis and cerebral amyloid angiopathy (CAA) are major pathologies. White matter hyperintensities, recent small subcortical infarcts, lacunes of presumed vascular origin, enlarged perivascular space, microbleeds, and brain atrophy are neuroimaging hallmarks of cSVD. The current primary approach to cSVD treatment is to control vascular risk factors such as hypertension, dyslipidemia, diabetes, and smoking. However, causal therapeutic strategies have not been established partly due to the heterogeneous pathogenesis of cSVD. In this review, we summarize the pathophysiology of cSVD and discuss the probable etiological pathways by focusing on hypoperfusion/hypoxia, blood-brain barriers (BBB) dysregulation, brain fluid drainage disturbances, and vascular inflammation to define potential diagnostic and therapeutic targets for cSVD.

Indexed as

Alzheimer DiseaseCerebral Small Vessel DiseasesDementia, VascularCausalityHumansRisk FactorsArteriolosclerosisBlood–brain barriers (BBB)Cerebral amyloid angiopathy (CAA)Cerebral small vessel disease (cSVD)Glymphatic drainageHypoperfusion/HypoxiaIntramural periarterial drainage (IPAD)Vascular cognitive impairment and dementia (VCID)Vascular inflammation

Identifiers

PMID37434208
PMCPMC10334598
OpenAlexW4383906895

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.